{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.1"}]}],"title":"End of Induction period Ia"},{"categories":[{"measurements":[{"groupId":"OG000","value":"88.7"}]}],"title":"End of Induction period Ib"},{"categories":[{"measurements":[{"groupId":"OG000","value":"93.4"}]}],"title":"End of Consolidation period"}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"}],"units":"Participants"}],"description":"Complete Remission rate is defined as the percentage of participants achieving a complete remission, i.e. \\< 5% lymphoblasts in bone marrow and in CSF, with no evidence of other extramedullary disease. Complete remission will be assessed at the end of Induction IA, end of induction IB and end of the consolidation period for all treated participants.","groups":[{"description":"Children and adolescents newly diagnosed with Philadelphia chromosome positive acute lymphocytic leukemia (Ph+ ALL) treated with standard multiagent chemotherapy and Dasatinib (either in tablets or Powder For Oral Suspension (PFOS)) at a dose of 60 mg/m2 daily.","id":"OG000","title":"Dasatinib Cohort"}],"paramType":"NUMBER","populationDescription":"All treated participants","reportingStatus":"POSTED","timeFrame":"From first dose to End of Induction Period Ia (up to 5 weeks) or Ib (up to 9 weeks) or End of Consolidation Period (up to 22 weeks)","title":"Complete Remission Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Partcipants"}